Regencell Bioscience Holdings Limited
RGC
$32.00
-$2.34-6.81%
NASDAQ
| 06/30/2024 | 03/31/2024 | 06/30/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | 4.80M | 4.69M | 4.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 6.27M | 7.39M | 7.50M |
| Operating Income | -- | -- | -6.27M | -7.39M | -7.50M |
| Income Before Tax | -- | -- | -6.06M | -7.25M | -7.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -6.06 | -7.25 | -7.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 191.20K | 169.00K | 158.80K |
| Net Income | -- | -- | -5.87M | -7.08M | -7.26M |
| EBIT | -- | -- | -6.27M | -7.39M | -7.50M |
| EBITDA | -- | -- | -6.09M | -7.27M | -7.41M |
| EPS Basic | -- | -- | -0.45 | -0.54 | -0.56 |
| Normalized Basic EPS | -- | -- | -0.13 | -0.18 | -0.18 |
| EPS Diluted | -- | -- | -0.45 | -0.54 | -0.56 |
| Normalized Diluted EPS | -- | -- | -0.13 | -0.18 | -0.18 |
| Average Basic Shares Outstanding | -- | -- | 52.05M | 52.07M | 51.65M |
| Average Diluted Shares Outstanding | -- | -- | 52.05M | 52.07M | 51.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |